Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions

• Published in: Drug metabolism and disposition Vol. 49; no. 12; pp. 1070 - 1080
• Main Authors: Nasrin, Shamema, Watson, Christy J.W., Perez-Paramo, Yadira X, Lazarus, Philip
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2021; The American Society for Pharmacology and Experimental Therapeutics
• Subjects: Biotransformation; Cannabidiol - metabolism; Cannabinoids - classification; Cannabinoids - metabolism; Cannabinol - metabolism; Cannabis; Cytochrome P-450 Enzyme Inhibitors - pharmacokinetics; Cytochrome P-450 Enzyme System - analysis; Cytochrome P-450 Enzyme System - classification; Dronabinol - analogs & derivatives; Dronabinol - metabolism; Drug Interactions - physiology; Glucuronosyltransferase - metabolism; HEK293 Cells; Hepatobiliary Elimination - drug effects; Humans; FDA; Km; UGT; CBD; AUCRhep; HLM; MS/MS; CBN; THC; AUC; AUCRsys; THC-COOH; 7-OH-CBD; TDI; P450; CBD-COOH; fu, inc; MS; IS; 11-OH-THC; HEK; CB1; HIV; UPLC; LC; THC-COO-Gluc; Ki

The legalization of cannabis in many parts of the United States and other countries has led to a need for a more comprehensive understanding of cannabis constituents and their potential for drug-drug interactions. Although (−)-trans-Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (C...